Johnson & Johnson Warns New Drug Deals Will Hit 2027 Earnings
Johnson & Johnson beats Q3 2026 earnings expectations with $25.39B in sales and raises its full-year revenue and profit guidance.
Share
Why It Matters
Johnson & Johnson made more money than expected this quarter. But they said future drug deals will cost them money later on.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.